MedImmune presents "A diamond in the rough – trends and strategies in the healthcare VC market"at 2010 BIO International Convention in Chicago


MedImmune will lead a panel discussion at the 2010 BIO International Convention entitled, “A Diamond in the Rough – Trends and Strategies in the Healthcare VC Market,” which will take a deep dive into  current and future trends surrounding traditional and non-traditional investment funding including:

  • How VC investment strategies will evolve considering the recent healthcare legislation
  • The impact of the recession and drought in IPOs on VC funding and why VC funding in the biotech industry is less susceptible to the pitfalls of a financial slowdown
  • Venture capitalists’ investment criteria and how it is shaped during economic cycles
  • The increasing hands-on approach of VC firms and what VCs look for when they invest in a start-up company
  • Opportunities for life science entrepreneurs within this changing market and the secrets of raising cash in a buyers market



MedImmune’s Eva Jack, Managing Director of MedImmune Ventures, Inc, will lead the roundtable panel discussion with participants to include:

  • Steven Elms, MBA, Managing Partner, Aisling Capital LLC
  • Allan Marchington, PhD, Partner, Apposite Capital
  • Carole Nuechterlein, Head of Roche Venture Fund  for F. Hoffmann – La Roche Ltd
  • Joseph Regan  VP Investments: Life Sciences for GrowthWorks Capital



With the current recession and lack of IPOs in the market, venture capital investment impacts every non-public biotech company.



Tuesday, May 4th
4:00PM to 5:30PM



Room: S405B, McCormick Place
2301 S. Lake Shore Drive
Chicago, IL  60616


*Please note this panel takes place in a different room from other BIO finance track sessions